NCT06405087View on ClinicalTrials.gov

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 27, 2025

Primary Completion Date

January 26, 2032

Study Completion Date

January 26, 2032

Conditions
Ulcerative ColitisCrohn's Disease
Interventions
DRUG

Vedolizumab SC

Vedolizumab subcutaneous injection.

OTHER

No Intervention

As this is an observational cohort, no intervention will be administered.

Sponsors

Lead Sponsor

Takeda
All Listed Sponsors
lead

Takeda

INDUSTRY